CoChat

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Open access
Wei, Yan, Chang, Lijia, Hashimoto, Kenji · 2022 · Molecular Psychiatry

The DOI matches its Crossref record; 189 of the 191 references it cites were found in a registry or an index.

Abstract

The discovery of robust antidepressant actions exerted by the N -methyl-D-aspartate receptor (NMDAR) antagonist ( R,S )-ketamine has been a crucial breakthrough in mood disorder research. ( R,S )-ketamine is a racemic mixture of equal amounts of ( R )-ketamine (arketamine) and ( S )-ketamine (esketamine). In 2019, an esketamine nasal spray from Johnson & Johnson was approved in the United States of America and Europe for treatment-resistant depression. However, an increasing number of preclinical studies show that arketamine has greater potency and longer-lasting antidepressant-like effects than esketamine in rodents, despite the lower binding affinity of arketamine for the NMDAR. In clinical trials, non-ketamine NMDAR-related compounds did not exhibit ketamine-like robust antidepressant actions in patients with depression, despite these compounds showing antidepressant-like effects in rodents. Thus, the rodent data do not necessarily translate to humans due to the complexity of human psychiatric disorders. Collectively, the available studies indicate that it is unlikely that NMDAR plays a major role in the antidepressant action of ( R,S )-ketamine and its enantiomers, although the precise molecular mechanisms underlying antidepressant actions of ( R,S )-ketamine and its enantiomers remain unclear. In this paper, we review recent findings on the molecular mechanisms underlying the antidepressant actions of ( R,S )-ketamine and its potent enantiomer arketamine. Furthermore, we discuss the possible role of the brain–gut–microbiota axis and brain–spleen axis in stress-related psychiatric disorders and in the antidepressant-like action of arketamine. Finally, we discuss the potential of arketamine as a treatment for cognitive impairment in psychiatric disorders, Parkinson’s disease, osteoporosis, inflammatory bowel diseases, and stroke.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01121-1

Cites

189 of 189 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Major metabolisms of ketamine enantiomers. Arketamine is metabolized to (R)-norketamine that is metabolized to (2 R,6 R)-hydroxynorketamine (HNK). In addition, arketamine is also metabolized to (2 R,6 R)-hydroxyketamine that is metabolized (2 R,6 R)-HNK. Esketamine is metabolized to (S)-norketamine that is metabolized to (2 S,6 S)-HNK. In addition, esketamine is metabolized to (2 S,6 S)-hydroxyketamine that is metabolized to (2 S,6 S)-HNK. Ki values for NMDAR are presented in parenthesis [46, 49].
Fig. 1 Major metabolisms of ketamine enantiomers. Arketamine is metabolized to (R)-norketamine that is metabolized to (2 R,6 R)-hydroxynorketamine (HNK). In addition, arketamine is also metabolized to (2 R,6 R)-hydroxyketamine that is metabolized (2 R,6 R)-HNK. Esketamine is metabolized to (S)-norketamine that is metabolized to (2 S,6 S)-HNK. In addition, esketamine is metabolized to (2 S,6 S)-hydroxyketamine that is metabolized to (2 S,6 S)-HNK. Ki values for NMDAR are presented in parenthesis [46, 49].CC BY · PubMed Central
Fig. 2 Proposed signaling pathways underlying the antidepressant-like actions of arketamine and TGF-β1. Arketamine induces the expression of TGF-β1 in the microglia through unidentified mechanisms. Arketamine-induced TGF-β1 or TGF-β1 bind to its receptor TGF-β receptor 1/2 in the microglia. Subsequently, released BDNF binds to its receptor TrkB, resulting in MEK–ERK–CREB signaling pathway, leading to synaptogenesis and antidepressant actions. MEK: mitogen-activated protein kinase, ERK: extracellular signal-regulated kinase, CREB: cAMP response element binding protein.
Fig. 2 Proposed signaling pathways underlying the antidepressant-like actions of arketamine and TGF-β1. Arketamine induces the expression of TGF-β1 in the microglia through unidentified mechanisms. Arketamine-induced TGF-β1 or TGF-β1 bind to its receptor TGF-β receptor 1/2 in the microglia. Subsequently, released BDNF binds to its receptor TrkB, resulting in MEK–ERK–CREB signaling pathway, leading to synaptogenesis and antidepressant actions. MEK: mitogen-activated protein kinase, ERK: extracellular signal-regulated kinase, CREB: cAMP response element binding protein.CC BY · PubMed Central
Fig. 3 Role of brain–gut–microbiota axis and brain–spleen axis in the stress-related psychiatric disorders and beneficial effects by arketamine. Repeated stress caused gut microbiota dysbiosis and an increase in spleen size and weight, resulting in abnormalities in immune system. Stress-induced neuroinflammation might be mediated by the brain–gut–microbiota axis and the brain–spleen axis through the vagus nerve. Interestingly, arketamine could ameliorate the abnormalities of gut microbiota, abnormal functions of the spleen, and depressive symptoms in patients with stress-related disorders. A slight modification from the previous report [44]. Some materials of the figure have been designed using resources from Freepik.com.
Fig. 3 Role of brain–gut–microbiota axis and brain–spleen axis in the stress-related psychiatric disorders and beneficial effects by arketamine. Repeated stress caused gut microbiota dysbiosis and an increase in spleen size and weight, resulting in abnormalities in immune system. Stress-induced neuroinflammation might be mediated by the brain–gut–microbiota axis and the brain–spleen axis through the vagus nerve. Interestingly, arketamine could ameliorate the abnormalities of gut microbiota, abnormal functions of the spleen, and depressive symptoms in patients with stress-related disorders. A slight modification from the previous report [44]. Some materials of the figure have been designed using resources from Freepik.com.CC BY · PubMed Central
Fig. 4 Potential of arketamine for cognitive impairments in psychiatric disorders and other diseases. Preclinical findings suggest that arketamine would be a new therapeutic drug for cognitive impairments in psychiatric disorders, neurodegenerative disorders such as Parkinson’s disease, osteoporosis, IBDs (ulcerative colitis and Crohn’s disease), and stroke. Importantly, patients with these diseases have depressive symptoms as comorbidity. IBD is a risk factor for PD [180]. Some materials of the figure have been designed using resources from Freepik.com.
Fig. 4 Potential of arketamine for cognitive impairments in psychiatric disorders and other diseases. Preclinical findings suggest that arketamine would be a new therapeutic drug for cognitive impairments in psychiatric disorders, neurodegenerative disorders such as Parkinson’s disease, osteoporosis, IBDs (ulcerative colitis and Crohn’s disease), and stroke. Importantly, patients with these diseases have depressive symptoms as comorbidity. IBD is a risk factor for PD [180]. Some materials of the figure have been designed using resources from Freepik.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 189 references

Research works printed but not linked: 1

  1. Press release: Perception Neuroscience’s PCN-101 (R-ketamine) demonstrates tolerability in phase 1 single ascending dose study. https://www.perceptionns.com/news.

Cited by

See all 251

Metadata

Authors
Wei, Y., Chang, L., & Hashimoto, K.
Affiliations
Chiba University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Molecular Psychiatry
Published
2021-05-07
Volume
27
Issue
1
Pages
559-573
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3158143766
Cited by
248
References
191
Citations by year
2026: 23 · 2025: 51 · 2024: 58 · 2023: 43 · 2022: 55 · 2021: 18
FWCI
5.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP20dm0107119)
  • National Natural Science Foundation of China (31701009)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, antidepressant mechanism, NMDA receptor, treatment-resistant depression, brain-gut-microbiota axis, stress-related psychiatric disorders, cognitive impairment, Parkinson's disease, osteoporosis, inflammatory bowel disease, stroke
MeSH terms
Antidepressive Agents, Depression, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. https://app.cochat.ai/papers/10.1038/s41380-021-01121-1
The paper
Wei, Y., Chang, L., & Hashimoto, K. (2022). Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01121-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.